Breast cancers can be classified into subgroups that hint at the aggressiveness of the cancer and the likelihood that the ...

(Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the prevention and treatment of breast cancer ... development, we will focus on continuing to get ...

If the trial is successful, the firm's complete estrogen receptor antagonist would complement its other biomarker-driven breast cancer assets.

By age 75, a noteworthy 50% of men develop an inguinal (groin) hernia - a bulge that results from soft tissue pushing through a weak spot in the abdominal muscles.

Discover the role of phytoestrogens, including soy, in menopause management and breast cancer prevention. Learn how these ...

Novartis’ Kisqali (ribociclib) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) to treat a ...

A global pharmaceutical company partnered with DelveInsight to create a robust and simplified solution enabling its top ...

Olema Pharmaceuticals, Inc. (“Olema” or “”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast ...

Leerink Partners maintained an Outperform rating on Arvinas Inc. (NASDAQ:ARVN) but reduced the price target from $62.00 to ...

Shares of BriaCell Therapeutics Corp. (NASDAQ: BCTX) climbed 10% following the announcement of a significant clinical response in the first patient treated with B ...

Seiji Wakao, JPMorgan, queried the feasibility of achieving ¥1 trillion in oncology revenue amid Datroway’s setbacks. Ogawa stated that ENHERTU’s performance could potentially fill the gap, with a ...